Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Marina Mitsui"'
Autor:
Hiroshi Suemizu, Megumi Nishiwaki, Marina Mitsui, Hiroshi Yamazaki, Miho Yamazaki-Nishioka, Makiko Shimizu
Publikováno v:
Xenobiotica. 48:117-123
1. Benzydamine is used clinically as a nonsteroidal anti-inflammatory drug in oral rinses and is employed in preclinical research as a flavin-containing monooxygenase (FMO) probe substrate. In this study, plasma concentrations of benzydamine and its
Autor:
Masahiro Utoh, Tomonori Miura, Yasuhiro Uno, Takahiro Hirano, Takashi Kusama, Marina Mitsui, Hiroshi Yamazaki, Makiko Shimizu, Mirai Kawano
Publikováno v:
Xenobiotica. 48:206-210
1. Cynomolgus monkey cytochrome P450 2C19 (formerly known as P450 2C75), homologous to human P450 2C19, has been identified as R-warfarin 7-hydroxylase. In this study, simulations of R-warfarin clearance in individual cynomolgus monkeys genotyped for
Autor:
Makiko Shimizu, Hiroshi Yamazaki, Norio Shibata, Marina Mitsui, F. Peter Guengerich, Hiroshi Suemizu
Publikováno v:
Xenobiotica. 47:844-848
1. Pomalidomide has been shown to be potentially teratogenic in thalidomide-sensitive animal species such as rabbits. Screening for thalidomide analogs devoid of teratogenicity/toxicity - attributable to metabolites formed by cytochrome P450 enzymes
Autor:
Shotaro Uehara, Erika Sasaki, Makiko Shimizu, Yasuhiro Uno, Mirai Kawano, Masahiro Utoh, Marina Mitsui, Akiko Toda, Hiroshi Suemizu, Hiroshi Yamazaki
Publikováno v:
Xenobiotica. 46:1049-1055
1. The pharmacokinetic data of cytochrome P450 probes in humans can be extrapolated from corresponding data in cynomolgus monkeys, dogs and minipigs using simplified physiologically based pharmacokinetic (PBPK) modeling. In this study, the modeling m
Autor:
Amit S. Kalgutkar, Shinichi Ninomiya, Satoshi Ito, Hidetaka Kamimura, Marina Mitsui, Sho Nishinoaki, Yosuke Yamamoto, Tomohiro Ishiguro, Hiroshi Yamazaki, Takeshi Okuzono, Hiroyuki Chijiwa, Hiroshi Suemizu
Publikováno v:
Xenobiotica; the fate of foreign compounds in biological systems. 47(5)
1. The partial glucokinase activator N,N-dimethyl-5-((2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzofuran-4-yl)oxy)pyrimidine-2-carboxamide (PF-04937319) is biotransformed in humans to N-methyl-5-((2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzo
Publikováno v:
Chemical research in toxicology. 29(12)
Species differences exist in terms of drug oxidation activities, which are mediated mainly by cytochrome P450 (P450) enzymes. To overcome the problem of species extrapolation, transchromosomic mice containing a human P450 3A cluster or chimeric mice
Publikováno v:
Chemical Research in Toxicology; Dec2016, Vol. 29 Issue 12, p1903-1911, 9p